Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
68 filings of BIOCON since November 2024; the newest 40 below.
board outcome 28, presentation 14, transcript 8, credit rating 7, acquisition 7, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 11 Nov 2026 | transcript Guidance, Management change, Results | Biocon Limited has informed the Exchange about TranscriptAI summaryBiocon filed the transcript of its Q2 FY27 earnings call held on November 4, 2026, with the transcript also posted on its website. Management (Chairperson Kiran Mazumdar Shaw and CEO Shreehas Tambe) said the company is moving from investment-led capability building to commercial acceleration and expects H2 FY27 to be stronger than H1. Management reported Q2 FY27 consolidated operating revenue growth of 2% year-on-year and H1 FY27 consolidated operating revenue of INR8,725 crores (up 6% year-on-year), with H1 EBITDA of INR1,767 crores (20% margin). Management said Q2 biosimilars revenue was INR2,809 crores and generics revenue INR774 crores, with about 5% of quarterly revenue deferred on logistics issues and booked in October. Management also announced leadership changes, including Rhonda Duffy retiring as COO in March 2027 and George Kaliviotis succeeding her from April 2027. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | presentation Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon Limited filed its investor presentation for the Q2 FY27 earnings call held on November 4, 2026. Q2 FY27 revenue from operations was ₹4,389 Cr (up 2% YoY, up 1% QoQ); total revenue ₹4,423 Cr; EBITDA ₹865 Cr with a 20% margin (vs 22% a year ago). Q2 FY27 net profit before exceptional items was ₹44 Cr (down 52% YoY); reported net profit was ₹41 Cr. H1 FY27 revenue from operations was ₹8,725 Cr (up 6% YoY); H1 FY27 net profit before exceptional items was ₹189 Cr (up 42% YoY). Management said H1 FY27 execution milestones strengthen the foundation for a stronger H2, including additional insulin capacity, and cited the positive CHMP opinion and Genentech settlement for Pertuzumab as providing greater visibility on commercialization. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | board outcome Management change, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.AI summaryBiocon's board approved unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2026, along with a limited review report from the statutory auditors. Board noted the resignation of Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer (Senior Management Personnel), effective close of business on December 31, 2026. Board approved the appointment of Mr. Mukesh Rathi as Chief Technology Officer (Senior Management Personnel), effective January 01, 2027, on the recommendation of the Nomination and Remuneration Committee. Mukesh Rathi previously served as Group Chief Digital Officer at Hinduja Group and, earlier, in senior leadership roles at Dr. Reddy's Laboratories, including Global Chief Digital and Information Officer. The board meeting commenced at 11:20 A.M. and concluded at 1:10 P.M. on November 4, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | board outcome Management change, Results | Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryBoard of Biocon Limited approved the unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2026, with the statutory auditors' limited review report enclosed. Board noted the resignation of Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer (Senior Management Personnel), effective close of business on December 31, 2026. Board approved the appointment of Mr. Mukesh Rathi as Chief Technology Officer (Senior Management Personnel), effective January 01, 2027, on the recommendation of the Nomination and Remuneration Committee. Mukesh Rathi's profile states over 27 years of leadership experience and that he was previously Group Chief Digital Officer at Hinduja Group and, earlier, Global Chief Digital and Information Officer at Dr. Reddy's Laboratories. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2026 | transcript Guidance, Results | Biocon Limited has informed the Exchange about TranscriptAI summaryBiocon filed the transcript of its Q1 FY27 earnings call held on August 06, 2026, along with a cover letter to BSE and NSE. On the call, management said group operating revenue grew 10% year-on-year, with biopharmaceuticals up 17% and services revenue down 16%. Management reported group EBITDA of INR902 crores (21% margin), interest cost of INR213 crores (down 23% year-on-year), and reported net profit before exceptionals of INR145 crores (up 245% year-on-year). Biosimilars revenue was INR2,855 crores (up 16%) with EBITDA of INR728 crores (25% margin); generics revenue was INR760 crores (up 21%) with EBITDA of INR56 crores (7% margin). Syngene revenue fell 16% year-on-year to INR736 crores; management expects single-digit rupee revenue degrowth for FY27 and EBITDA margins back to mid-20s. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Aug 2026 | presentation Dividend / buy-back, Guidance, Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon filed the presentation for its Q1 FY27 earnings call held on August 06, 2026. Q1 FY27 revenue from operations was ₹4,336 Cr, up 10% YoY and down 4% QoQ; EBITDA was ₹902 Cr (21% margin) versus ₹846 Cr a year earlier. Q1 FY27 net profit before exceptional items was ₹145 Cr versus ₹42 Cr in Q1 FY26; reported net profit was ₹141 Cr. Biosimilars revenue was ₹2,855 Cr (up 16% YoY), with EBITDA margin of 25%; management expects growth momentum to build through FY27, with H2 to be meaningfully better. Management said recent US launches and market access progress provide visibility on a stronger second half. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | board outcome Results | Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBiocon's board approved unaudited standalone and consolidated Ind-AS financial results for the quarter ended June 30, 2026, at a meeting held on August 05, 2026 (2:30 p.m. to 3:34 p.m.), with a limited review report from the statutory auditors enclosed. Consolidated revenue from operations for Q1 FY27 was Rs. 43,360 million, against Rs. 45,166 million in the quarter ended March 31, 2026 and Rs. 39,419 million in the quarter ended June 30, 2025. Consolidated net profit for the quarter was Rs. 1,368 million, against Rs. 1,986 million in the prior quarter and Rs. 892 million in the year-ago quarter; profit attributable to shareholders of the Company was Rs. 1,411 million. Consolidated basic EPS for the quarter was Rs. 0.87 (not annualised), against Rs. 0.79 in the prior quarter and Rs. 0.26 in the year-ago quarter. Standalone revenue from operations for the quarter was Rs. 6,245 million, and standalone net profit was Rs. 116 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jun 2026 | acquisition Acquisition, Capex | Biocon Limited has informed the Exchange about AcquisitionAI summaryBiocon Limited completed acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited (BBL) from 127 selling shareholders on June 29, 2026. Consideration was settled by preferential allotment of 87,86,362 equity shares of Biocon of Rs. 5 each at an issue price of Rs. 376.41 per share, under shareholder approval dated June 07, 2026. Post allotment, paid-up equity share capital rose from Rs. 8,10,45,38,865 to Rs. 8,14,84,70,675 (1,62,96,94,135 shares). BBL became a wholly-owned subsidiary of Biocon w.e.f. June 29, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Jun 2026 | acquisition Acquisition, Capex | Biocon Limited has informed the Exchange about AcquisitionAI summaryBiocon Limited has acquired equity stake in Ampin C&I Power Twelve Private Limited (AMPIN), a newly incorporated SPV for solar power generation, formed April 23, 2025. The Company invested Rs. 5,47,60,000 (Rs. 54.76 crore) in 54,76,000 equity shares of face value Rs. 10 each at par, paid in cash. Post-investment, the Company will hold 59,76,000 shares, or 37.77% of AMPIN's paid-up capital (undiluted); this reduces to 15.91% on a fully diluted basis after other investors come in. AMPIN will set up a 27.12 MW (DC) solar plant in Karnataka; the acquisition is not a related party transaction and no governmental approvals are required. Management said the stake is to enhance renewable power consumption, maintain captive status under the Electricity Act, and reduce energy cost and carbon footprint. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Jun 2026 | presentation Guidance | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon Limited filed an investor presentation dated June 2026 under Regulation 30 of the SEBI LODR Regulations, for analyst and institutional investor meetings scheduled on June 02, 2026 and June 08, 2026. Company profile per the presentation: over 47 years of legacy, presence in 120+ countries, 11 manufacturing locations, and $1,924M in FY26 revenues. Revenue mix in FY26: Generics 60%, Biosimilars 22%, CRDMO services 18%. Biocon holds a 52.4% stake in Syngene and a 9.8% stake in Bicara Therapeutics; Syngene is listed and Bicara is NASDAQ-listed. The presentation describes the integration of Biocon Limited and Biocon Biologics, combining generics and biosimilars into one business with 30+ biosimilars and 3 GLP-1s in the portfolio. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2026 | transcript Acquisition, Capex, Guidance, Results | Biocon Limited has informed the Exchange about TranscriptAI summaryBiocon filed the transcript of its Q4 FY26 earnings call held on May 08, 2026, with the BSE and NSE, also posted on its website. Management said Q4 FY26 operating revenue grew 10% year-on-year excluding the one-time generic lenalidomide bonus in Q4 FY25; EBITDA was INR1,073 crores with a 23% margin, up 29% year-on-year on an adjusted basis. Management reported Q4 FY26 net profit before exceptionals of INR179 crores and FY26 net profit before exceptionals of INR436 crores. Management said the biosimilars business revenue was INR2,756 crores in Q4 FY26, up 12% year-on-year, with EBITDA of INR720 crores at a 26% margin; generics revenue was INR847 crores with EBITDA of INR75 crores; CRDMO revenue was INR1,037 crores, up 2% year-on-year. Management said the major investment phase is substantially complete and it expects performance to improve progressively through FY27, especially in the second half. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 May 2026 | presentation Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon filed its Q4 FY26 earnings call presentation (dated May 08, 2026) under Regulation 30, for the call held the same day. Q4 FY26 revenue from operations was ₹4,517 Cr (up 10% YoY, 8% QoQ); biosimilars ₹2,756 Cr, generics ₹847 Cr, CRDMO ₹1,037 Cr. Q4 FY26 EBITDA was ₹1,073 Cr (23% margin) and reported net profit was ₹126 Cr, versus ₹344 Cr in Q4 FY25. FY26 revenue from operations was ₹16,927 Cr (up 13% YoY on an adjusted basis) and FY26 EBITDA was ₹3,798 Cr (22% margin). Management said FY26 was a "clear inflection point", that integration of Biocon Biologics into Biocon is complete, and that the major capacity build-out is substantially complete, with focus shifting to utilization and margin expansion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 May 2026 | board outcome Acquisition, Dividend / buy-back, Guidance, Legal, Management change, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.AI summaryBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of face value Rs. 5) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board recommended appointment of S. R. Batliboi & Associates LLP as Statutory Auditors for five years (48th AGM to 53rd AGM, 2031), replacing B S R & Co. LLP. Board approved designation of Dr. Anuj Goel (Chief Development Officer) and Mr. Susheel Umesh (Chief Commercial Officer – Emerging Markets and Head of Global API & Global BD) as Senior Management Personnel; recommended appointment of five Independent Directors and one Non-Executive Non-Independent Director effective August 01, 2026, and re-appointment of Ms. Rekha Mehrotra Menon as Independent Director, all subject to shareholder approval. Board approved acquisition of the remaining ~2% stake in Biocon Biologics Limited via preferential issue of up to 87,92,317 equity shares at Rs. 376.16 per share (aggregate up to Rs. 330.73 crore), and conversion of OCDs and CCDs of BBL into equity shares; also approved Long-Term Incentive Plans 2026 and set the 48th AGM for August 06, 2026, all subject to approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 May 2026 | board outcome Acquisition, Capex, Dividend / buy-back, Management change, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026-AcquisitionAI summaryBoard of Biocon Limited on May 07, 2026 approved audited standalone and consolidated results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of Re. 0.50 per equity share (10% on face value of Rs. 5), with record date July 03, 2026 and payment on or before August 31, 2026, subject to AGM approval. The Board recommended appointment of S. R. Batliboi & Associates LLP as Statutory Auditors for five years, replacing B S R & Co. LLP, subject to shareholder approval. The Board approved re-appointment of Ms. Rekha Mehrotra Menon as Independent Director for a second five-year term, and recommended appointment of five Independent Directors and one Non-Executive Non-Independent Director effective August 01, 2026, subject to shareholder approval via postal ballot. The Board approved a preferential issue of up to 87,92,317 equity shares at Rs. 376.16 per share (aggregate up to Rs. 330.73 crore) to acquire the remaining ~2% stake in Biocon Biologics Limited, plus conversion of OCDs and CCDs of BBL into equity, and approved a Long-Term Incentive Plan 2026; the 48th AGM is scheduled for August 06, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 May 2026 | board outcome Acquisition, Dividend / buy-back, Legal, Management change, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.AI summaryBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of face value Rs. 5) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board recommended appointment of S. R. Batliboi & Associates LLP as Statutory Auditors for five years, from the 48th AGM to the 53rd AGM in 2031, replacing B S R & Co. LLP. Board approved re-appointment of Ms. Rekha Mehrotra Menon as Independent Director for a second five-year term from August 06, 2026, and recommended appointment of five Independent Directors and one Non-Executive Non-Independent Director (Thomas Jason Roberts) effective August 01, 2026, in connection with integration with Biocon Biologics Limited; all subject to shareholder approval by Postal Ballot. Board approved acquisition of up to 87,92,317 Biocon equity shares at Rs. 376.16 per share via preferential issue, aggregating up to Rs. 330.73 crore, for remaining ~2% stake in Biocon Biologics Limited; also approved conversion of OCDs and CCDs of BBL into equity shares, and a Long-Term Incentive Plan 2026, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 May 2026 | dividend Acquisition, Dividend / buy-back, Legal, Management change, Results | Biocon Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 0.5 per equity share.AI summaryBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of Rs. 5 face value) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board recommended appointment of S. R. Batliboi & Associates LLP as statutory auditors for five years (48th to 53rd AGM), replacing B S R & Co. LLP. Board approved preferential issue of up to 87,92,317 equity shares at Rs. 376.16 per share (aggregate up to Rs. 330.73 crore) to acquire remaining ~2% stake in Biocon Biologics Limited; relevant date May 08, 2026. Board approved conversion of OCDs and CCDs of Biocon Biologics into 4,11,11,689 and 1,06,86,044 equity shares respectively, and recommended appointment of several independent and non-independent directors effective August 01, 2026, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 May 2026 | board outcome Acquisition, Dividend / buy-back, Legal, Management change, Results | Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Biocon Limited approved audited standalone and consolidated results for the quarter and financial year ended March 31, 2026. Board recommended a final dividend of 10% (Re. 0.50 per equity share of Rs. 5 face value) for FY2026, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board recommended appointment of S. R. Batliboi & Associates LLP as statutory auditors for five years (48th AGM to 53rd AGM, 2031), replacing B S R & Co. LLP. Board approved preferential issue of up to 87,92,317 equity shares at Rs. 376.16 per share (aggregate up to Rs. 330.73 crore) to acquire the remaining ~2% stake in Biocon Biologics Limited from its employees and other shareholders, subject to shareholder approval. Board approved conversion of OCDs and CCDs of Biocon Biologics into 4,11,11,689 and 1,06,86,044 equity shares respectively, and recommended appointment of several new directors, including Thomas Jason Roberts, and approval of a Long-Term Incentive Plan 2026; the 48th AGM is on August 06, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Mar 2026 | board outcome Management change | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Key Managerial Personnels who are authorized to determine materiality of an event or information and make necessary disclosures to the StocAI summaryBiocon Limited's board on March 27, 2026 accepted the resignation of Siddharth Mittal as CEO and Managing Director, effective close of business March 31, 2026, to take another role in the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional Director w.e.f. April 1, 2026 and as CEO and MD for 5 years from April 1, 2026, subject to shareholder approval. Mukesh Kamath resigned as Interim CFO effective close of business March 31, 2026; Kedar Narayan Upadhye, CFO of Biocon Biologics, appointed CFO w.e.f. April 1, 2026. Akhilesh Nand designated KMP and Head, Governance, Risk and Compliance w.e.f. April 1, 2026; Naveen Narayanan and Mandar Shrikant Ghatnekar named Chief Human Resources Officer and Chief Technology Officer w.e.f. April 1, 2026. Seven senior management personnel ceased to hold that role effective close of business March 31, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Mar 2026 | board outcome Management change | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Change in KMP and SMPAI summaryBiocon Limited's board, at its meeting on March 27, 2026, accepted the resignation of Siddharth Mittal as CEO and Managing Director effective close of business March 31, 2026, to move to another role in the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional Director effective April 1, 2026 and as CEO and MD for five years from April 1, 2026, subject to shareholder approval. Board accepted resignation of Mukesh Kamath as Interim CFO effective March 31, 2026, and appointed Kedar Narayan Upadhye, CFO of Biocon Biologics, as CFO effective April 1, 2026. Akhilesh Nand, Company Secretary of Biocon Biologics, designated Head, Governance, Risk and Compliance as KMP from April 1, 2026; Naveen Narayanan and Mandar Shrikant Ghatnekar designated Chief Human Resources Officer and Chief Technology Officer as senior management from April 1, 2026. Seven senior management personnel ceased in that role effective close of business March 31, 2026, and the board revised the list of KMPs authorised to determine materiality of events and make stock exchange disclosures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Mar 2026 | board outcome Management change | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CFO and Resignation of Interim FOAI summaryBoard of Biocon Limited, meeting held March 27, 2026, accepted resignation of Siddharth Mittal as CEO and Managing Director effective close of business March 31, 2026, to take another role within the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional Director w.e.f. April 01, 2026 and as CEO and MD for five years from April 01, 2026, subject to shareholder approval. Board accepted resignation of Mukesh Kamath as Interim CFO effective close of business March 31, 2026, and approved appointment of Kedar Narayan Upadhye as CFO w.e.f. April 01, 2026. Akhilesh Nand designated Head, Governance, Risk and Compliance and KMP from April 01, 2026; Naveen Narayanan and Mandar Shrikant Ghatnekar designated CHRO and CTO respectively from April 01, 2026. Seven senior management personnel ceased in that role effective close of business March 31, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Mar 2026 | board outcome Management change | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CEO and MD, and resignation of CEO and MD.AI summaryBiocon Limited's board on March 27, 2026 accepted the resignation of Siddharth Mittal as CEO and Managing Director, effective close of business March 31, 2026, to take another role within the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional Director from April 01, 2026 and as CEO and MD for five years from April 01, 2026, subject to shareholder approval. Mukesh Kamath resigned as Interim Chief Financial Officer effective close of business March 31, 2026; Kedar Narayan Upadhye, CFO of Biocon Biologics Limited, appointed CFO from April 01, 2026. Akhilesh Nand designated Head, Governance, Risk and Compliance as KMP from April 01, 2026; Naveen Narayanan and Mandar Shrikant Ghatnekar designated Chief Human Resources Officer and Chief Technology Officer as senior management from April 01, 2026. Seven senior management personnel ceased from close of business March 31, 2026, and the board revised the list of KMPs authorised to determine materiality of events from April 01, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Mar 2026 | acquisition Acquisition, Capex | Biocon Limited has informed the Exchange about AcquisitionAI summaryBiocon Limited filed under Regulation 30 that on March 3, 2026 it acquired 11,53,44,285 OCRPS of Rs 10 each from wholly owned subsidiary Biocon Biosphere Limited and 20,00,00,000 OCRPS of Rs 10 each from wholly owned subsidiary Biocon Pharma Limited, both at issue price Rs 10 each. Total consideration for the Biocon Biosphere Limited OCRPS is Rs 1,15,34,42,850, made up of Rs 20,00,00,000 in cash and Rs 95,34,42,850 by way of set-off of an earlier loan of Rs 93,10,00,000 plus accrued interest. Cash consideration for the Biocon Pharma Limited OCRPS is Rs 2,00,00,00,000. Biocon states the investments fund ongoing business requirements, including working capital and capex for Biocon Biosphere and working capital and general corporate requirements for Biocon Pharma; both subsidiaries are 100% owned and no regulatory approvals are required. FY 2024-25 turnover was Rs 130 Mn for Biocon Biosphere Limited and Rs 9,825 Mn for Biocon Pharma Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Feb 2026 | presentation Acquisition, Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon Limited filed an investor presentation dated February 2026 for analyst and institutional investor meetings scheduled on February 25 and 26, 2026, under Regulation 30 of the SEBI Listing Regulations. The presentation reports FY25 revenue of $1,806M, with 9MFY26 revenue mix of 61% Generics, 21% Biosimilars, 18% CRDMO Services. It cites 120+ countries of global reach, 215+ cGMP approvals, 11 manufacturing locations and 1,500+ patents. It outlines the planned integration of Biocon Limited and Biocon Biologics, combining generics and biosimilars businesses, with a portfolio of 30+ biosimilars and 3 GLP-1s. Market caps cited: Biocon $6.8 bn, Syngene $1.9 bn (Biocon holds 52.4%), Bicara $0.8 bn (Biocon holds 10.1%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Feb 2026 | transcript Acquisition, Rating, Results | Biocon Limited has informed the Exchange about TranscriptAI summaryBiocon filed the transcript of its Q3 FY26 earnings call held on February 13, 2026. Management said operating revenue was INR 4,173 crores, up 9% year-on-year, with Core EBITDA of INR 1,221 crores (29% margin) and reported net profit of INR 144 crores for the quarter. Management said the planned merger of Biocon Biologics with Biocon follows the acquisition of Viatris biosimilars business, with Biocon Biologics valued at USD 5.5 billion. Management said S&P upgraded Biocon Biologics' long-term issuer credit rating to BB+ (stable) on January 27, 2026, and Fitch revised its outlook to positive; annualized interest savings of about INR 300 crores are expected from FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | presentation Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon filed the presentation for its Q3 FY26 earnings call held on February 13, 2026. Q3 FY26 revenue from operations was ₹4,173 Cr, up 9% YoY and down 3% QoQ; total revenue was ₹4,290 Cr; Core EBITDA was ₹1,221 Cr (29% margin) versus ₹1,007 Cr a year earlier. Q3 FY26 net profit before exceptional items was ₹124 Cr versus ₹13 Cr in Q3 FY25; reported net profit was ₹144 Cr. Biocon Biologics Q3 FY26 segment revenue was ₹2,497 Cr (up 9% YoY) with EBITDA of ₹700 Cr (28% margin), up 44% YoY. Management said the acquisition-related leverage has been addressed, major capex is largely behind, and operating leverage is beginning to play out. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | board outcome Acquisition, Capex, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.AI summaryBoard of Biocon Limited approved the un-audited standalone and consolidated Ind-AS financial results for the quarter and nine months ended December 31, 2025, on February 12, 2026. Standalone Q3 FY26 revenue from operations was Rs 6,213 million and standalone net loss was Rs (764) million, against a net profit of Rs 5,840 million in the year-ago quarter (which included exceptional items). Consolidated Q3 FY26 revenue from operations was Rs 41,730 million and consolidated net loss was Rs (518) million, against a net profit of Rs 811 million in the year-ago quarter. Board granted in-principle approval to acquire the remaining ~2% of Biocon Biologics Limited's equity from Biocon Group employees and other shareholders, with consideration by preferential allotment of Company equity shares, subject to shareholder and regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | board outcome Acquisition, Dividend / buy-back, Results | Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryBiocon Limited's board on February 12, 2026 approved the unaudited standalone and consolidated Ind-AS results for the quarter and nine months ended December 31, 2025. Standalone: Q3 FY26 revenue from operations Rs 6,213 million and net loss Rs (764) million, against a net profit of Rs 5,840 million in Q3 FY25; nine-month net loss Rs (138) million. Consolidated: Q3 FY26 revenue from operations Rs 41,730 million and net loss attributable to shareholders' profit of Rs 1,438 million; net loss for the period Rs (518) million, with non-controlling interest loss of Rs (1,956) million. The board granted in-principle approval to acquire the remaining ~2% of Biocon Biologics Limited's equity from group employees and other shareholders, to be paid by preferential allotment of Biocon equity shares, subject to shareholder and regulatory approvals. Following this, Biocon Biologics Limited would become a wholly owned subsidiary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jan 2026 | acquisition Acquisition | Biocon Limited has informed the Exchange about Update on AcquisitionAI summaryBiocon Limited filed a Regulation 30 disclosure on completion of the acquisition of the balance 7,18,34,691 equity shares of Biocon Biologics Limited (BBL) from Mylan Inc. The consideration for this tranche is cash of USD 200 million, completed on January 21, 2026. This is the second tranche of the acquisition of 14,36,69,382 BBL equity shares from Mylan Inc. approved by the Board on December 06, 2025, for total cash consideration of USD 400 million. Post the acquisition, the company holds about 98% of the paid-up equity share capital of BBL on a fully diluted basis. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Jan 2026 | acquisition Acquisition, Capex | Biocon Limited has informed the Exchange about Acquisition of equity shares of Biocon Biologics LimitedAI summaryBiocon Limited filed an update on the acquisition of equity shares of Biocon Biologics Limited (BBL), an unlisted material subsidiary, and a preferential allotment of Biocon shares, both completed on January 05, 2026. Biocon acquired 26,19,17,480 BBL equity shares from Mylan Inc., Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II and Activ Pine LLP, and allotted 17,12,79,553 Biocon equity shares of Rs. 5 each to them at Rs. 405.78 per share as consideration. Post allotment, Biocon's issued and paid-up equity share capital rose from Rs. 6,68,48,18,175 to Rs. 7,54,12,15,940, with 1,50,82,43,188 equity shares outstanding. Biocon also completed acquisition of 7,18,34,691 further BBL shares from Mylan for cash consideration of USD 200 million, out of a balance of 14,36,69,382 shares approved for USD 400 million. After these acquisitions Biocon holds 33,37,52,171 BBL shares, about 94% of BBL's paid-up equity share capital on a fully diluted basis. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Dec 2025 | credit rating Rating | Biocon Limited has informed the Exchange about Credit RatingAI summaryBiocon Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit rating. CRISIL Ratings Limited reaffirmed the credit ratings on the Company's bank facilities. Total bank loan facilities rated: Rs. 250 Crore. Long term rating: Crisil AA+/Stable (reaffirmed); short term rating: Crisil A1+ (reaffirmed). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Dec 2025 | credit rating Acquisition, Capex, Rating | Biocon Limited has informed the Exchange about Credit RatingAI summaryBiocon Limited filed intimation of a credit rating from ICRA Limited dated December 16, 2025. ICRA assigned [ICRA]AA+(Stable)/[ICRA]A1+ on Rs. 450.00 crore of Long Term/Short Term unallocated instruments, with the amount unchanged from the previous rated amount. The rating rationale cites Biocon's proposed acquisition of minority stakes in Biocon Biologics Limited (BBL) from Mylan Inc., Serum Institute Life Sciences, Tata Capital and Activ Pine, valued at about $1.17 billion, to make BBL a wholly-owned subsidiary. Funding includes a share swap of 171.3 million Biocon shares (about Rs. 6,950 crore) and a $400 million cash payment to Mylan Inc., with $200 million funded via commercial paper and $200 million via a QIP of up to Rs. 4,500 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Dec 2025 | credit rating Rating | Biocon Limited has informed the Exchange about Credit RatingAI summaryBiocon Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings, citing India Ratings and Research's press release dated December 09, 2025. India Ratings assigned IND AA+/Stable/IND A1+ to bank loan facilities of INR 5,500 million and assigned IND A1+ to proposed commercial paper of INR 8,000 million. India Ratings withdrew the rating on non-convertible debentures of INR 10,700 million, as the instrument has been paid in full. India Ratings affirmed IND AA+/Stable/IND A1+ on bank loan facilities of INR 4,500 million and IND A1+ on proposed commercial paper of INR 12,000 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Dec 2025 | presentation Acquisition, Guidance | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon Limited filed an investor presentation (December 2025) under Regulation 30 ahead of analyst/institutional investor meetings scheduled for December 10 and 11, 2025. The presentation covers a proposed consolidation of Biocon Limited and Biocon Biologics, combining biosimilars, insulins, peptides and complex generics into one structure, with CRDMO services kept as a separate offering. Management states the consolidation aims to simplify the corporate structure, remove the HoldCo discount, and create operational synergies and a larger balance sheet. Per the presentation, H1FY26 revenue mix is 62% biosimilars, 17% generics and 21% CRDMO services; Biocon has a market cap of $6.1 bn as of December 3, 2025. Management says Biocon Biologics minority shareholders would benefit from an earlier liquidity event. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Dec 2025 | acquisition | Biocon Limited has informed the Exchange about Acquisition | NSE copy |
| 06 Dec 2025 | presentation | Biocon Limited has informed the Exchange about Presentation | NSE copy |
| 06 Dec 2025 | board outcome | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on December 06, 2025. | NSE copy |
| 18 Nov 2025 | transcript Acquisition, Dividend / buy-back, Guidance, Results | Biocon Limited has informed the Exchange about TranscriptAI summaryBiocon filed the transcript of its Q2 FY26 earnings call held on November 12, 2025, with the cover letter dated November 18, 2025. Management said operating revenue was INR 4,296 crores, up 20% year-on-year, with core EBITDA of INR 1,218 crores (28% margin) and reported EBITDA of INR 928 crores (21% margin). Management said biosimilar revenue was INR 2,721 crores (up 25% year-on-year), generics revenue INR 774 crores (up 24%), and Syngene (CRDMO) revenue INR 911 crores (up 2%). Management said debt settlements with Goldman Sachs and Kotak are expected to save around INR 300 crores in annual interest costs from FY27. Management said it expects margins to keep improving in Q3 and Q4 FY26 and that Syngene is maintaining its FY26 annual guidance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | presentation Acquisition, Capex, Guidance, Legal, Results | Biocon Limited has informed the Exchange about Investor PresentationAI summaryBiocon filed the presentation for its Q2 FY26 earnings call held on November 12, 2025. Q2 FY26 revenue from operations was ₹4,296 crore, up 20% YoY and 9% QoQ; total revenue was ₹4,389 crore; EBITDA was ₹928 crore (21% margin); net profit before exceptional items was ₹92 crore versus a loss of ₹13 crore in Q2 FY25. Biosimilars segment revenue was ₹2,721 crore (up 25% YoY); Generics was ₹774 crore (up 24%); CRDMO was ₹911 crore (up 2%). Management said it settled structured debt with Goldman Sachs and Kotak using QIP proceeds, with annual interest savings of about ₹300 crore expected from FY27. Management said it received US FDA approval and a settlement and license agreement with Amgen for bDenosumab in the U.S., and expects an imminent launch of bDenosumab. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Nov 2025 | board outcome Acquisition, Capex, Legal, Results | Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 11, 2025.AI summaryBiocon filed the outcome of its board meeting held November 11, 2025, approving the unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2025. Board approved early full redemption of 50,000 secured rated NCDs of Rs 1,00,000 each, aggregating Rs 500 crores (issued May 19, 2023), subject to approvals on or before January 31, 2026. Board approved acquisition of 1,06,86,044 compulsorily convertible debentures of Biocon Biologics Limited, an unlisted material subsidiary, from ESOF III Investment Fund and EAAA India Alternatives Limited for Rs 300 crores on or before January 30, 2026, increasing the company's holding in BBL by about 65 basis points. Board approved issuance of commercial papers up to Rs 550 crores in one or more tranches on private placement basis. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Nov 2025 | board outcome Acquisition, Capex, Dividend / buy-back, Results | Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBiocon Limited filed the outcome of its board meeting held on November 11, 2025, approving the unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2025. The board approved early full redemption of 50,000 secured rated NCDs of Rs. 1,00,000 each, aggregating Rs. 500 Crores, issued on May 19, 2023, subject to approvals on or before January 31, 2026. The company will acquire 1,06,86,044 compulsorily convertible debentures of Biocon Biologics Limited, an unlisted material subsidiary, from ESOF III Investment Fund and EAAA India Alternatives Limited for Rs. 300 Crores on or before January 30, 2026, increasing its holding in BBL by about 65 basis points. The board approved issuance of commercial papers up to Rs. 550 Crores in one or more tranches on a private placement basis. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.